

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai - 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
www.sunpharma.com
CIN : L24230GJ1993PLC019050



November 10, 2016

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.
NSE Code – SUNPHARMA

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.
BSE Code– 524715

Dear Sirs,

Sub: Outcome of the Board Meeting held on November 10, 2016

1. The Board of Directors of the Company at their meeting held today approved and took on record the Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the Second quarter and half year ended September 30, 2016. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the Second quarter and half year ended September 30, 2016 along with Limited Review Report of the Auditors on Standalone and Consolidated Financial Results.
2. The Board of Directors of the Company on the recommendation of the Audit Committee held today prior to the board Meeting, approved, subject to receipt of further approvals of the hon'ble High Court of Gujarat or the National Company Law Tribunal ("High Court"), as the case may be, Stock Exchanges, Securities and Exchange Board of India and all other requisite parties/authorities, the Scheme of Arrangement for amalgamation of Sun Pharma Medisales Private Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited and Vidyut Investments Limited, which are direct or indirect wholly owned subsidiaries of the Company, into Sun Pharmaceutical Industries Limited in terms of Sections 391 to 394 or any other applicable provisions, if any, of the Companies Act, 1956 and/or the corresponding provisions of Companies Act, 2013 ("Scheme"), as the case may be, with appointed date of April 01, 2017 or such other date as may be agreed/required by the Transferor Companies and the Transferee Company and/or by the High Court.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the disclosures of information required are enclosed under **Annexure A**.

The meeting of the Board of Directors commenced on November 10, 2016 at 11:00 a.m. and concluded at 03:25 p.m.

This is for your information and record.

Thanking you,

Yours faithfully,

For Sun Pharmaceutical Industries Ltd.

A handwritten signature in black ink, appearing to read 'A I Bhuta', with a horizontal line extending to the right.

Ashok I. Bhuta
Compliance Officer

Encl: As above

Disclosure of information pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015

- a) Name of the entity(ies) forming part of the amalgamation/merger, details in brief such as size, turnover etc.:

Transferor Companies: The Transferor Companies are direct or indirect wholly owned subsidiaries, of the Company and shall get amalgamated into the Company in terms of Sections 391 to 394 or any other applicable provisions, if any, of the Companies Act, 1956 and/or the corresponding provisions of Companies Act, 2013 as may be applicable. The Transferor Companies are:

1. Sun Pharma Medisales Private Limited;
2. Ranbaxy Drugs Limited;
3. Gufic Pharma Limited; and
4. Vidyut Investments Limited.

Transferee Company: Sun Pharmaceutical Industries Limited

(Rs. in Lakhs)

Particulars	Transferee Company	Transferor Company 1	Transferor Company 2	Transferor Company 3	Transferor Company 4
Name of the company	Sun Pharmaceutical Industries Limited	Sun Pharma Medisales Private Limited ⁽¹⁾	Ranbaxy Drugs Limited	Gufic Pharma Limited	Vidyut Investments Limited
Net worth As on March 31, 2016	21,48,309	18,275.84	18,533.46	42.58	262.92
Net worth as on September 30, 2016 ⁽²⁾	21,61,873	177.08 ⁽³⁾	18,921.91	43.65	269.01
Total Revenue (including other income) for the year ended March 31, 2016	8,04,628	12,857.91	1,236.00	4.16	20.06
Total Revenue (including other income) for the half year ended September 30, 2016 ⁽²⁾	4,22,806	5859.9 ⁽⁴⁾	390.25	2.03	10.08

Notes:

- (1) Erstwhile partnership firm in the name and style of "Solrex Pharmaceuticals Company" and converted into a Company w.e.f. September 23, 2016 under the provisions of Companies Act, 2013.
- (2) The numbers has been calculated as per Indian Accounting Standards ("Ind AS").

- (3) On conversion of the erstwhile partnership firm in the name and style of "Solrex Pharmaceuticals Company" into company w.e.f. September 23, 2016, the partners' capital account being part of net worth amounting to Rs. 18653.8 Lakhs has been converted into loans from these partners, Transferor Company 2 and Transferor Company 3 by the Transferor Company 1 and on the merger being effective the same would get cancelled.
- (4) The amount includes the revenue from the erstwhile partnership firm Solrex Pharmaceuticals Company from the period of April 01, 2016 to September 22, 2016.

b) Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length"?

The Transferor Companies are direct or indirect wholly owned subsidiaries, of the Transferee Company. Therefore, they are related parties but the Transferee Company shall not be required to issue any shares or pay any consideration to the Transferor Companies or to its shareholders.

c) Area of business of the entity(ies):

Sun Pharmaceutical Industries Limited: Manufacturing and Marketing of Pharmaceutical Products

Sun Pharma Medisales Private Limited: Manufacturing and Trading of Pharmaceutical Products

Ranbaxy Drugs Limited: Investment in Pharmaceutical Business

Gufic Pharma Limited: Pharmaceutical Business

Vidyut Investments Limited: Investment Business

d) Rationale for amalgamation/ merger;

All Transferor Companies are direct or indirect wholly-owned subsidiaries, of the Transferee Company. In order to consolidate and effectively manage the Transferor Companies and the Transferee Company in a single entity, which will provide several benefits including synergy, economies of scale, attain efficiencies and cost competitiveness, it is intended that the Transferor Companies be amalgamated with Transferee Company. The amalgamation of Transferor Companies with Transferee Company would inter alia have the following benefits:

- (a) The amalgamation will lead to greater efficiency in overall combined business including economies of scale, efficiency of operations, cash flow management and unfettered access to cash flow generated by the combined business which can be deployed more efficiently for the purpose of development of businesses of the combined entity and their growth opportunities, eliminate inter corporate dependencies, minimize the administrative compliances and to maximize shareholders value.

- (b) The amalgamation will provide for more productive and optimum utilization of various resources by pooling of the managerial, technical and financial resources of the Transferor Companies and the Transferee Company which will fuel the growth of the business and help effectively address the ever growing competition.
- (c) The amalgamation will result in economy of scales, reduction in overheads including administrative, managerial and other expenditure, operational rationalization, organizational efficiency and optimal utilization of resources by elimination of unnecessary duplication of activities and related costs.
- (d) The amalgamation will result in a reduction in the multiplicity of legal and regulatory compliances required at present to be separately carried out by the Transferor Companies and the Transferee Company.
- (e) The amalgamation would motivate employees of the Transferor Companies by providing better opportunities to scale up their performance with a larger corporate entity having large revenue base, resources, asset base etc. which will boost employee morale and provide impetus to better corporate performance ultimately enhancing overall shareholder value.

The Transferor Companies and Transferee Company intend to / can achieve larger product portfolio, economies of scale, efficiency, optimisation of logistic and distribution network and other related economies by consolidating the business operations being managed by different management teams.

e) In case of cash consideration – amount or otherwise share exchange ratio;

The entire share capital (equity share capital as well as preference share capital, where applicable) of the Transferor Companies is held by the Company's wholly-owned subsidiary companies or by the Transferee Company itself. In other words, the Transferor Companies are the direct or indirect wholly-owned subsidiary companies of the Transferee Company. Accordingly, pursuant to this Scheme, no shares of the Transferee Company shall be issued and allotted in respect of shares held by it or its subsidiary companies in the Transferor Companies.

f) Brief details of change in shareholding pattern (if any) of listed entity.

As stated in clause e) above, no shares of the Transferee Company shall be issued and allotted pursuant to scheme of arrangement and thus there will be no change in the shareholding pattern of the listed company/Transferee Company.

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SUN PHARMACEUTICAL INDUSTRIES LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SUN PHARMACEUTICAL INDUSTRIES LIMITED** ("the Company"), for the quarter and half year ended September 30, 2016 and Standalone Unaudited Statement of Assets and Liabilities as at September 30, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. We have not performed a review or audit, as stated in Note 9 to the Statement, of the figures relating to the corresponding quarter and half year ended September 30, 2015, including the reconciliation of net loss for the quarter and half year ended September 30, 2015 between the previous GAAP and Indian Accounting Standards ("Ind AS"), as reported in this Statement.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.


2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

EH *my* *ml*
PKB

4. Remuneration to the Managing Director and a Whole-time Director of the Company for the year ended March 31, 2015 is in excess of the limits specified under Schedule V to the Act by ₹ 207 Lakhs. In this regard, we have been informed by the Management of the Company that they have made further representations to the Central Government of India in respect of their applications for approving the amounts of maximum remuneration for the three years ending March 31, 2017, including for the excess amounts already paid. The response in respect of the foregoing is awaited from the Central Government of India.

Our review report is not modified in respect of this matter.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani
Partner
(Membership No. 36920)

MUMBAI, November 10, 2016



Sun Pharmaceutical Industries Limited
Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390020.
Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324.
CIN: L24230GJ1993PLC019050, Website : www.sunpharma.com

Statement of Standalone Unaudited Financial Results for the Quarter and Half year ended September 30, 2016

(₹ in Lakhs)

Particulars	Quarter ended			Half year ended	
	30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
Income from Operations					
Sales / Income from Operations (inclusive of excise duty)	198,477	173,858	183,126	372,335	371,158
Other Operating Income	4,459	3,971	4,665	8,430	21,507
Total Income from Operations	202,936	177,829	187,791	380,765	392,665
Expenses					
Cost of materials consumed	43,508	50,293	53,810	93,801	107,745
Purchases of stock-in-trade	37,417	30,408	30,761	67,825	56,609
Changes in inventories of finished goods, work-in-progress and stock-in-trade	7,714	(6,880)	(10,529)	834	(10,483)
Employee benefits expense	35,177	36,734	35,963	71,911	82,227
Depreciation and amortisation expense	10,317	10,500	11,987	20,817	22,955
Other expenses	78,742	74,079	108,406	152,821	199,574
Total Expenses	212,875	195,134	230,398	408,009	458,627
Loss from Operations before Other Income, Finance Costs and Exceptional Item	(9,939)	(17,305)	(42,607)	(27,244)	(65,962)
Other income	29,400	12,641	1,103	42,041	6,596
Profit/(Loss) from ordinary activities before Finance Costs and Exceptional Item	19,461	(4,664)	(41,504)	14,797	(59,366)
Finance costs	719	10,137	18,211	10,856	32,577
Profit/(Loss) from ordinary activities after Finance Costs but before Exceptional Item	18,742	(14,801)	(59,715)	3,941	(91,943)
Exceptional item	-	-	-	-	7,013
Profit/(Loss) from ordinary activities before Tax	18,742	(14,801)	(59,715)	3,941	(98,956)
Tax expense	288	345	308	633	702
Net Profit/(Loss) for the period	18,454	(15,146)	(60,023)	3,308	(99,658)
Other Comprehensive Income (OCI) (net of tax)	(1,940)	(2,574)	(300)	(4,514)	(734)
Total Comprehensive Income for the period	16,514	(17,720)	(60,323)	(1,206)	(100,392)
Paid-up Equity Share Capital - Face Value ₹ 1 each	24,067	24,067	24,064	24,067	24,064
Earnings Per Share of ₹ 1 each					
₹ (Basic)	0.8	(0.6)	(2.5)	0.1	(4.1)
₹ (Diluted)	0.8	(0.6)	(2.5)	0.1	(4.1)
See accompanying notes to the standalone unaudited financial results					
Research & Development Expenses incurred (included above)	26,688	20,947	21,823	47,635	43,802

EH *Signature*
Signature



Sun Pharmaceutical Industries Limited

Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390020.

Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324.

CIN: L24230GJ1993PLC019050, Website : www.sunpharma.com

Statement of Standalone Unaudited Financial Results for the Quarter and Half year ended September 30, 2016

Notes :

1 Standalone Unaudited Statement of Assets and Liabilities

(₹ in Lakhs)

Particulars	As at 30.09.2016 Unaudited
I ASSETS	
A. Non-current Assets	
(a) Property, Plant and Equipment	359,361
(b) Capital Work-in-Progress	81,413
(c) Intangible Assets	5,040
(d) Financial Assets	
(i) Investments	2,008,231
(ii) Loans	737
(iii) Other Financial Assets	11,941
(e) Deferred Tax Assets (Net)	75,170
(f) Non-current tax Assets	108,345
(g) Other Non-current Assets	47,600
Total Non-Current Assets (A)	2,697,838
B. Current Assets	
(a) Inventories	219,557
(b) Financial Assets	
(i) Investments	17,072
(ii) Trade Receivables	253,195
(iii) Cash and Cash Equivalents	19,272
(iv) Bank balances other than (iii) above	1,657
(v) Loans	2,429
(vi) Other Financial Assets	7,214
(c) Other Current Assets	110,264
Total Current Assets (B)	630,660
TOTAL - ASSETS (A+B)	3,328,498
II EQUITY AND LIABILITIES	
A. Equity	
(a) Equity Share Capital	24,067
(b) Other Equity	2,137,806
Total Equity (A)	2,161,873
B. Liabilities	
Non-current Liabilities	
(a) Financial Liabilities	
Borrowings	67,567
(b) Provisions	130,581
(c) Other Non-Current Liabilities	57
Total Non-current Liabilities	198,205
Current Liabilities	
(a) Financial Liabilities	
(i) Borrowings	275,029
(ii) Trade Payables	206,647
(iii) Other Financial Liabilities	250,825
(b) Provisions	172,306
(c) Other Current Liabilities	63,613
Total Current Liabilities	968,420
Total Liabilities (B)	1,166,625
TOTAL - EQUITY AND LIABILITIES (A+B)	3,328,498

EH *my* *pl*
PKH



Sun Pharmaceutical Industries Limited

Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390020.

Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324.

CIN: L24230GJ1993PLC019050, Website : www.sunpharma.com


Statement of Standalone Unaudited Financial Results for the Quarter and Half year ended September 30, 2016**Notes :**

- 2 The above standalone unaudited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 10, 2016. The statutory auditors of the Company have conducted a "Limited Review" of the above standalone unaudited financial results for the quarter and half year ended September 30, 2016.
- 3 The Company has adopted Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, from April 01, 2016 and accordingly, these standalone unaudited financial results (including figures for the quarter and half year ended September 30, 2015) have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India.
- 4 During the half year ended September 30, 2016, 25,460 equity shares of ₹ 1 each have been allotted under Employee Stock Option Scheme of the Company.
- 5 The Board of Directors of the Company approved a proposal for buyback of equity shares at its meeting held on June 23, 2016. Further to the said approval, the Company completed buyback of 7,500,000 equity shares of ₹ 1 each (representing 0.31% of total pre buy back paid up equity capital) on October 18, 2016, from the shareholders on a proportionate basis by way of a tender offer at a price of ₹ 900 per equity share for an aggregate amount of ₹ 67,500 Lakhs in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy Back of Securities) Regulations, 1998.
- 6 The Company has only one reportable segment namely 'Pharmaceuticals'.
- 7 Reconciliation of net loss for the quarter and half year ended September 30, 2015 under Indian GAAP (Previous GAAP) and Ind AS is as under:

Particulars	(₹ in Lakhs)	
	Quarter ended 30.09.2015 Unaudited	Half year ended 30.09.2015 Unaudited
Net loss as per Previous GAAP	(60,132)	(98,842)
Add / (Less) : Adjustments for GAAP Differences		
Impact of measuring financial instruments at fair value through profit or loss	481	(290)
Unwinding effect of discounted long term provision	(885)	(1,845)
Other Ind AS adjustments	513	1,319
Net loss for the period as per Ind AS	(60,023)	(99,658)

- 8 As approved by the Members of the Company at the 24th Annual General Meeting held on September 17, 2016, the Company has disbursed, on September 21, 2016, dividend of ₹ 1 per equity share of the face value of ₹ 1 each aggregating ₹ 24,068 Lakhs. The corporate tax on such dividend aggregates ₹ 747 Lakhs, computed in terms of Section 115-O read with sub-sections 1 and 1A of the Income tax Act, 1961.
- 9 The standalone financial results and other financial information for the quarter and half year ended September 30, 2015 have not been audited or reviewed by the statutory auditors. However, the management has exercised necessary due diligence to ensure that the standalone unaudited financial results provide a true and fair view of the Company's affairs.

For and on behalf of the Board



Dilip S. Shanghvi
Managing Director

Mumbai, November 10, 2016

E11 24/11/16
RKB



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SUN PHARMACEUTICAL INDUSTRIES LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SUN PHARMACEUTICAL INDUSTRIES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the loss of its joint ventures and associates for the quarter and half year ended September 30, 2016 and the Consolidated Unaudited Statement of Assets and Liabilities as at September 30, 2016 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. We have not performed a review or audit, as stated in Note 5 to the Statement, of the figures relating to the corresponding quarter and half year ended September 30, 2015, including the reconciliation of net profit for the quarter and half year ended September 30, 2015 between the previous GAAP and Indian Accounting Standards ("Ind AS"), as reported in this Statement.

This Statement which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. The Statement includes the results of the entities as given in the Annexure to this review report.

EH AM ml
RCH

4. We did not review the interim financial information of 53 subsidiaries (51 subsidiaries for the quarter ended September 30, 2016) included in the consolidated unaudited financial results, whose interim financial information reflect total assets of ₹ 3,713,214 Lakhs as at September 30, 2016, total revenues of ₹ 539,338 Lakhs and ₹ 1,089,489 Lakhs for the quarter and half year ended September 30, 2016, respectively, and total profit after tax (net) of ₹ 200,759 Lakhs and ₹ 422,592 Lakhs and total comprehensive income (net) of ₹ 144,309 Lakhs and ₹ 414,342 Lakhs for the quarter and half year ended September 30, 2016, respectively, as considered in the consolidated unaudited financial results.

The consolidated unaudited financial results also includes the Group's share of loss after tax of ₹ 1,678 Lakhs and ₹ 2,387 Lakhs and total comprehensive loss of ₹ 1,678 Lakhs and ₹ 2,387 Lakhs for the quarter and half year ended September 30, 2016, respectively, as considered in the consolidated unaudited financial results, in respect of 2 joint ventures and 2 associates, whose interim financial information / results have not been reviewed by us.

These interim financial information / results have been reviewed by other auditors whose reports have been furnished to us and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors.

5. Based on our review conducted as stated above and based on the consideration of the reports of the other auditors referred to in paragraph 4 above and based on the consideration of interim financial information furnished to us by the Management referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. Remuneration to the Managing Director and a Whole-time Director of the Parent for the year ended March 31, 2015 is in excess of the limits specified under Schedule V to the Act by ₹ 207 Lakhs. In this regard, we have been informed by the Management of the Parent that they have made further representations to the Central Government of India in respect of their applications for approving the amounts of maximum remuneration for the three years ending March 31, 2017, including for the excess amounts already paid. The response in respect of the foregoing is awaited from the Central Government of India.

Our review report is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim financial information of 53 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of ₹ 150,733 Lakhs as at September 30, 2016, total revenue of ₹ 32,672 Lakhs and ₹ 66,072 Lakhs for the quarter and half year ended September 30, 2016, respectively, and total loss after tax (net) of ₹ 2,655 Lakhs and ₹ 5,926 Lakhs and total comprehensive loss (net) of ₹ 4,807 Lakhs and ₹ 15,857 Lakhs

EH *ML*
RLK

for the quarter and half year ended September 30, 2016, respectively, as considered in the consolidated unaudited financial results.

The consolidated unaudited financial results also includes the Group's share of loss of ₹ Nil and ₹ Nil and total comprehensive income of ₹ Nil and ₹ Nil for the quarter and half year ended September 30, 2016, respectively, as considered in the consolidated unaudited financial results, in respect of 2 joint ventures and an associate (no associate for the quarter ended September 30, 2016), based on their interim financial information which have not been reviewed by their auditors.


The interim financial information in respect of these subsidiaries, joint ventures and an associate have been furnished to us by the Management. According to the information and explanations given to us by the Management, these financial information are not material to the Group.

Our review report on the Statement is not modified in respect of our reliance on the financial information certified by the Management.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani
Partner
(Membership No. 36920)



MUMBAI, November 10, 2016

**ANNEXURE TO THE INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF
INTERIM FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
SUN PHARMACEUTICAL INDUSTRIES LIMITED**

List of entities included in the consolidated unaudited financial results of Sun Pharmaceutical Industries Limited (the Parent) for the quarter and half year ended September 30, 2016, referred to in paragraph 3 of our review report dated November 10, 2016

Parent – Sun Pharmaceutical Industries Limited

Direct Subsidiaries

- 1 Green Eco Development Centre Limited
- 2 Sun Pharmaceutical (Bangladesh) Limited
- 3 Sun Pharmaceutical Industries, Inc.
- 4 Sun Farmaceutica do Brasil Ltda
- 5 Sun Pharma De Mexico S.A. DE C.V.
- 6 SPIL De Mexico S.A. DE C.V.
- 7 Sun Pharmaceutical Peru S.A.C.
- 8 OOO "Sun Pharmaceutical Industries" Limited.
- 9 Sun Pharma de Venezuela, C.A.
- 10 Sun Pharma Laboratories Limited
- 11 Faststone Mercantile Company Private Limited
- 12 Neetnav Real Estate Private Limited
- 13 Realstone Multitrade Private Limited
- 14 Skisen Labs Private Limited
- 15 Softdeal Trading Company Private Limited
- 16 Ranbaxy Pharmacie Generiques
- 17 Ranbaxy Drugs Limited
- 18 Vidyut Investments Limited
- 19 Gufic Pharma Limited
- 20 Ranbaxy (Malaysia) Sdn. Bhd.
- 21 Ranbaxy Nigeria Limited
- 22 Ranbaxy (Netherlands) B.V.
- 23 Sun Pharma Holdings

Step down Subsidiaries

- 24 Chattem Chemicals Inc.
- 25 Taro Development Corporation
- 26 Alkaloida Chemical Company Zrt.
- 27 Sun Pharmaceutical UK Ltd.
- 28 Sun Pharmaceutical Industries (Australia) Pty. Limited
- 29 Aditya Acquisition Company Ltd.
- 30 Sun Pharmaceutical Industries (Europe) B.V.
- 31 Sun Pharmaceuticals Italia S.R.L.
- 32 Sun Pharmaceutical Spain, S.L.U
- 33 Sun Pharmaceuticals Germany GmbH
- 34 Sun Pharmaceuticals France

EH *any* *ml*
PKK

35	Sun Pharma Global FZE
36	Sun Pharmaceuticals (SA) (Pty) Ltd.
37	Sun Global Canada Pty. Ltd.
38	Sun Pharma Philippines, Inc.
39	Sun Pharmaceuticals Korea Ltd.
40	Sun Global Development FZE
41	Caraco Pharmaceuticals Private Limited
42	Sun Pharma Japan Ltd
43	Sun Pharma HealthCare FZE
44	Morley and Company Inc
45	Sun Laboratories FZE
46	Taro Pharmaceutical Industries Ltd.
47	Taro Pharmaceuticals Inc.
48	Taro Pharmaceuticals U.S.A., Inc.
49	Taro Pharmaceuticals North America, Inc.
50	Taro Pharmaceuticals Europe B.V.
51	Taro Pharmaceuticals Ireland Limited
52	Taro International Ltd.
53	Taro Pharmaceuticals UK Ltd.
54	Taro Hungary Intellectual Property Licensing LLC.
55	3 Skyline LLC
56	One Commerce Drive LLC
57	Taro Pharmaceutical Laboratories Inc
58	Taro Pharmaceuticals Canada Ltd.
59	Taro Pharmaceutical India Private Limited
60	Alkaloida Sweden AB
61	Dusa Pharmaceuticals Inc
62	Dusa Pharmaceuticals New York Inc
63	Sirius Laboratories Inc
64	Mutual Pharmaceutical Company, Inc.
65	Dungan Mutual Associates, LLC
66	URL PharmPro, LLC
67	Universal Enterprises Private Ltd.
68	Sun Pharma Switzerland Limited
69	Sun Pharma East Africa Limited
70	Pharmalucence, Inc.
71	PI Real Estate Ventures, LLC
72	Ranbaxy Australia Pty Ltd.
73	Ranbaxy Farmaceutica Ltda.
74	Ranbaxy Pharmaceuticals Canada Inc.
75	Ranbaxy Egypt LLC
76	Rexcel Egypt (L.L.C.)
77	Office Pharmaceutique Industriel et Hospitalier
78	Basics GmbH
79	Ranbaxy GmbH
80	Ranbaxy Ireland Limited
81	Ranbaxy Italia S.P.A
82	Ranbaxy - PRP (Peru) S.A.C.
83	Ranbaxy (Poland) S.P. Zoo

EH *mm*

RLH

84	S.C Terapia S.A.
85	AO Ranbaxy
86	Ranbaxy South Africa Proprietary Limited
87	Ranbaxy Pharmaceuticals (Pty) Ltd.
88	Be-Tabs Investments Proprietary Limited.
89	Sonke Pharmaceuticals Proprietary Limited.
90	Laboratorios Ranbaxy, S.L.
91	Ranbaxy (U.K.) Limited.
92	Ranbaxy Holdings (UK) Ltd.
93	Ranbaxy Europe Limited
94	Ranbaxy Inc.
95	Ranbaxy Pharmaceuticals, Inc.
96	Ranbaxy (Thailand) Company Limited
97	Ohm Laboratories, Inc.
98	Ranbaxy Laboratories, Inc.
99	Ranbaxy Signature LLC
100	Sun Pharmaceuticals Morocco
101	Ranbaxy Pharmaceuticals Ukraine LLC
102	Insite Vision Inc.
103	Perryton Wind Power LLC (not applicable for the quarter ended September 30, 2016)
104	Insite Vision Ltd.
105	Sun Pharma Medisales Private Limited (formerly Solrex Pharmaceuticals Company)
106	2 Independence Way LLC
107	Foundation for Disease Elimination and Control of India

Associates

108	Zenotech Laboratories Limited
109	Medinstill LLC
110	Daiichi Sankyo (Thailand) Ltd. (not applicable for the quarter ended September 30, 2016)

Joint Ventures

111	MSD - Sun LLC
112	S & I Ophthalmic LLC
113	Artes Biotechnology GmbH

Subsidiary of Joint Ventures

114	MSD - Sun FZ LLC
-----	------------------

EH *[Signature]*
[Signature]

Statement of Consolidated Unaudited Financial Results for the Quarter and Half year ended September 30, 2016

(₹ in Lakhs)

Particulars	Quarter ended			Half year ended	
	30.09.16	30.06.16	30.09.15	30.09.16	30.09.15
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
Income from Operations					
Sales / Income from Operations (inclusive of excise duty)	776,403	800,668	685,816	1,577,071	1,338,501
Other Operating Income	50,109	23,631	1,513	73,740	24,976
Total Income from Operations	826,512	824,299	687,329	1,650,811	1,363,477
Expenses					
Cost of materials consumed	111,317	112,914	106,689	224,231	209,145
Purchases of stock-in-trade	61,270	81,225	99,849	142,495	162,697
Changes in inventories of finished goods, work-in-progress and stock-in-trade	11,399	(9,438)	(56,762)	1,961	(52,942)
Employee benefits expense	119,914	123,929	121,236	243,843	244,758
Depreciation and amortisation expense	30,383	31,595	25,843	61,978	49,863
Other expenses	205,843	223,571	229,023	429,414	435,740
Total Expenses	540,126	563,796	525,878	1,103,922	1,049,261
Profit from Operations before Other Income, Finance Costs and Exceptional Items	286,386	260,503	161,451	546,889	314,216
Other Income	11,940	15,710	11,524	27,650	27,935
Profit from ordinary activities before Finance Costs and Exceptional Items	298,326	276,213	172,975	574,539	342,151
Finance Costs	5,372	13,462	15,818	18,834	29,268
Profit from ordinary activities after Finance Costs but before Exceptional Items	292,954	262,751	157,157	555,705	312,883
Exceptional Items	-	-	-	-	68,517
Profit from ordinary activities before tax	292,954	262,751	157,157	555,705	244,366
Tax Expense	44,165	35,271	29,463	79,436	40,738
Net Profit for the period	248,789	227,480	127,694	476,269	203,628
Share of Profit / (Loss) of Associates and Joint Ventures	(1,678)	(709)	2,226	(2,387)	1,956
Net Profit after taxes and share of profit / (loss) of associates and joint ventures but before non-controlling interests (a)	247,111	226,771	129,920	473,882	205,584
Non-controlling Interests	23,597	23,400	27,038	46,997	47,112
Net Profit after taxes, non-controlling interests and share of profit / (loss) of associates and joint ventures	223,514	203,371	102,882	426,885	158,472
Other Comprehensive Income (OCI) (net of tax) (b)	(60,749)	37,654	43,409	(23,095)	91,400
Total Comprehensive Income for the period (a)+(b)	186,362	264,425	173,329	450,787	296,984
Paid-up Equity Share Capital					
Equity Shares - Face Value ₹ 1 each	24,067	24,067	24,064	24,067	24,064
Earnings Per Share of ₹ 1 each					
₹ (Basic)	9.3	8.5	4.3	17.7	6.6
₹ (Diluted)	9.3	8.4	4.3	17.7	6.6
See accompanying notes to the consolidated unaudited financial results					
Research & Development Expenses incurred (included above)	55,298	51,763	47,685	107,061	97,678

ANS EH AH
 RCB



Notes:

1 Consolidated Unaudited Statement of Assets and Liabilities

(₹ In Lakhs)

Particulars	As at 30.09.2016 Unaudited
I. ASSETS	
A. Non-current Assets	
(a) Property, Plant and Equipment	746,288
(b) Capital Work-In-Progress	154,112
(c) Goodwill	565,928
(d) Other Intangible Assets	278,671
(e) Intangible Assets under development	74,968
(f) Financial Assets	
(i) Investments	91,663
(ii) Loans	9,928
(iii) Other Financial Assets	282,172
(g) Deferred Tax Assets (Net)	389,449
(h) Non-current Tax Assets	148,380
(i) Other Non-current Assets	73,583
Total Non-current Assets (A)	2,815,142
B. Current Assets	
(a) Inventories	635,221
(b) Financial Assets	
(i) Investments	131,934
(ii) Trade Receivables	886,372
(iii) Cash and Cash Equivalents	768,712
(iv) Bank Balances other than (iii) above	504,588
(v) Loans	76,649
(vi) Others Financial Assets	12,111
(c) Current Tax Assets	16,050
(d) Other Current Assets	197,309
Total Current Assets (B)	3,228,946
TOTAL - ASSETS (A)+(B)	6,044,088
II. EQUITY AND LIABILITIES	
A. Equity	
(a) Equity Share Capital	24,067
(b) Other Equity	3,645,694
Equity Attributable to owners of the Company	3,669,761
(c) Non - Controlling Interests	369,956
Total Equity (A)	4,039,717
B. Liabilities	
Non-Current Liabilities	
(a) Financial Liabilities	
(i) Borrowings	185,998
(ii) Other Financial Liabilities	13,271
(b) Provisions	135,650
(c) Deferred Tax Liabilities (Net)	10,169
(d) Other Non-current Liabilities	2,514
Total Non-current Liabilities	347,602
Current Liabilities	
(a) Financial Liabilities	
(i) Borrowings	643,545
(ii) Trade Payables	358,212
(iii) Other Financial Liabilities	184,450
(b) Provisions	383,235
(c) Other Current Liabilities	59,754
(d) Current Tax Liabilities (Net)	27,573
Total Current Liabilities	1,656,769
Total Liabilities (B)	2,004,371
TOTAL - EQUITY AND LIABILITIES (A)+(B)	6,044,088

- 2 The above consolidated unaudited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 10, 2016. The statutory auditors of the Company have conducted a "Limited Review" of the above consolidated unaudited financial results for the quarter and half year ended September 30, 2016.
- 3 The Company adopted Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016 from April 01, 2016 and accordingly, these consolidated unaudited financial results (including figures for the quarter and half year ended September 30, 2015) have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India.
- 4 These consolidated unaudited financial results relate to Sun Pharmaceutical Industries Limited, its Subsidiaries (together constitute 'the Group'), Associates and Jointly Ventures and are prepared by applying IND AS 110 - "Consolidated Financial Statements", and IND AS 28 - "Investments in Associates and Joint Ventures".
- 5 The consolidated unaudited financial results and other financial information for the quarter and half year ended September 30, 2015 have not been audited or reviewed by the statutory auditors. However, the management has exercised necessary due diligence to ensure that the consolidated unaudited financial results provide a true and fair view of the Company's consolidated affairs.
- 6 The Group has only one reportable segment namely 'Pharmaceuticals'.

ANS

EH AMY

RKB



- 7 Reconciliation of net profit after taxes, non-controlling interest and share of loss of associates and joint ventures for the quarter and half year ended September 30, 2015 under IGAAP (Previous GAAP) and Ind AS is as under:

Particulars	₹ in Lakhs	
	Quarter ended 30.09.15 Unaudited	Half year ended 30.09.15 Unaudited
Net Profit as per IGAAP	110,666	158,562
Add / Less : adjustments for GAAP Differences		
Impact of measuring financial Instruments at fair value through profit or loss	(3,247)	(5,471)
Unwinding effect of discounted long term provision	(886)	(1,846)
Tax impact on Ind AS adjustments (including on unrealised intragroup profits on inventories)	4,082	15,487
Other Ind AS adjustments	(7,733)	(8,260)
Net Profit as reported under IND AS	102,882	158,472

- 8 The standalone unaudited financial results for the quarter and half year ended September 30, 2016, is available on the Company's website (www.sunpharma.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com) and the key information on the standalone unaudited financial results is as below:

Particulars	Quarter ended			Half year ended	
	30.09.16 Unaudited	30.06.16 Unaudited	30.09.15 Unaudited	30.09.16 Unaudited	30.09.15 Unaudited
Total Income from operations	202,936	177,829	187,791	380,765	392,665
Profit/(Loss) from ordinary activities before tax	18,742	(14,801)	(59,715)	3,941	(98,956)
Net Profit/(Loss) for the period	18,454	(15,146)	(60,023)	3,308	(99,658)

- 9 The Board of Directors of the Company approved a proposal for buyback of equity shares at its meeting held on June 23, 2016. Further to the said approval, the Company completed buyback of 7,500,000 equity shares of ₹ 1 each (representing 0.31% of total pre buy back paid up equity capital) on October 18, 2016, from the shareholders on a proportionate basis by way of a tender offer at a price of ₹ 900 per equity share for an aggregate amount of ₹ 67,500 lakhs in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy Back of Securities) Regulations, 1998.
- 10 Other comprehensive income (OCI) (net of tax) mainly include gains and losses arising from translating the financial information of foreign subsidiaries and gains and losses from investments in equity instruments designated at fair value through OCI.
- 11 As approved by the Members of the Company at the 24th Annual General Meeting held on September 17, 2016, the Company has disbursed on September 21, 2016, dividend of ₹ per equity share of face value of ₹ 1 each aggregating ₹ 24,068 Lakhs. The corporate tax on such dividend aggregates ₹ 4,900 Lakhs.
- 12 During the half year ended September 30, 2016, 25,460 equity shares of ₹ 1 each have been allotted under Employee Stock Option Scheme of the Company.

For and on behalf of the Board

[Signature]

Dilip S. Shanghvi
Managing Director

Mumbai, November 10, 2016



[Handwritten signature]